Drug Synthesis Articles & Analysis
10 news found
Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and moreChangsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and ...
By integrating artificial intelligence into drug synthesis, the AI-synthesizer not only accelerates the development timelines of small molecule drugs but also achieves greater precision and cost-efficiency. ...
Alfa Chemistry provides a wide variety of these intermediates which meet strict quality and safety requirements required for the drug development process. These intermediates (ammonium acids, organic acids, esters and heterocyclic compounds) allow us to innovate in drug synthesis, which in turn leads to more effective and precise ...
Specializing in drug formulation, the highly specialized CRO service provider CD Formulation has accumulated abundant experience in the custom synthesis of increased bioavailability excipients. ...
As an active player in the chemical industry, Alfa Chemistry decided to combine the power of computational chemistry with drug design and synthesis. This move aims to largely enhance the overall drug discovery efficiency and open up new possibilities for the pharmaceutical industry. ...
The potential applications are subject to the requisite clinical and regulatory commercialization processes. The global psychedelic drugs market is expected to gain significant market growth in the forecast period from 2022 to 2029. ...
He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. ...
Currently, its APIs & Intermediates mainly fall into two categories: featured APIs and patented original research drugs. The synthesis of featured APIs is admittedly more challenging than that of general ones. ...
Currently, its APIs & Intermediates mainly fall into two categories: featured APIs and patented original research drugs. The synthesis of featured APIs is admittedly more challenging than that of general ones. ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. Continued the design, synthesis and testing of new ...